BOSTON: AcuityMD has raised $80 million in a Series C round at a $955 million valuation to scale its AI platform for medical technology companies. StepStone Group led the round. Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management also participated. Total funding now exceeds $160 million.
The platform solves a specific commercial problem. MedTech companies operate in markets that shift fast, hospital consolidation, regulatory changes, and reimbursement updates can reshape the competitive landscape before any sales team can track it manually. AcuityMD aggregates claims databases, FDA filings, government records, and market signals into a proprietary knowledge graph, a continuously updated map of physicians, facilities, procedures, reimbursement dynamics, and the relationships between them.
That data foundation is what makes the AI layer defensible. More than 400 MedTech companies use the platform today, including 16 of the top 20 globally. Customers have used it to identify over $34 billion in commercial pipeline. General AI tools cannot replicate that kind of domain-specific context, and that is precisely the argument AcuityMD makes to enterprise buyers.
The new funding accelerates three priorities. First, it builds out AcuityAI, an agentic AI system currently in open beta that lets sales reps and commercial leaders query the platform in natural language and receive immediate, actionable territory plans. Second, it deepens the MedTech ontology powering the data model. Third, it expands the platform beyond commercial sales into the full product lifecycle, research, development, and launch phases for next-generation medical devices.
CEO Mike Monovoukas put the positioning simply. AI will transform MedTech, but only with the right context embedded in the workflows where decisions actually get made. AcuityMD’s claim is that it is that context layer.
Previous
